Evidence map›Paper›PMID 42854689›Full record

ArticleMolecular cell2026

Oligo(uridine) tailing and exonucleolytic decay drive 40S ribosome degradation in response to stress.

Frances F Diehl, Allen R Buskirk, Rachel Green

Abstract read
In one paragraph

Article in Molecular cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Frances F DiehlDepartment of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Allen R BuskirkDepartment of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Rachel GreenDepartment of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: ragreen@jhmi.edu.

Funding

The role of collisions in rescuing stalled ribosomes in bacteriaR01GM136960 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI Allen Rowdon Buskirk · 2021 to 2026
$1.9M
Regulation of ribosome homeostasis during cellular stress and cell type transitionsK99GM164738 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI Frances Flewelling Diehl · 2026 to 2026
$125k
NIGMS NIH HHS K99 GM164738NIGMS NIH HHS R01 GM136960
6 · The paper itself

Abstract

Stresses like starvation trigger degradation of mature 40S ribosomes, requiring the coordinated breakdown of large, stable RNA-protein complexes. The atypical kinase RIOK3 orchestrates degradation by binding ubiquitylated 40S ribosomes and promoting rRNA decay. However, the mechanisms and factors that mediate rRNA decay remain unknown. Here we find that in response to starvation, RIOK3 recruits the terminal uridylyl-transferase TUT7 and the exonuclease DIS3L2 to 40S ribosomes. Sequencing analyses show that TUT7 adds oligo(uridine) tails to the 3' end of 18S rRNA in these ribosomes. DIS3L2 subsequently recognizes uridylated 18S rRNA and carries out 3'-5' decay. We identify major decay intermediates that undergo further uridylation in a process of iterative uridylation and decay. Loss of DIS3L2 impairs 18S rRNA decay during starvation and leads to accumulation of uridylated 18S rRNA. Together these findings define a mechanism for ribosome degradation in human cells in which oligo(uridine) tailing drives decay of rRNA from ribosomes.

Indexed as

DIS3L2RibosomeRIOK3RNA decayrRNAstarvationstress responseTUT7uridylation

Identifiers

PMID42854689
PMCPMC13685426

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.